parimifasor

Parimifasor (formerly known as LYC-30937) is an orally administered, enteric-coated small molecule developed as a gut-directed ATPase modulator for the treatment of immune-mediated diseases, primarily ulcerative colitis. It acts as a potent immunomodulator by selectively inducing apoptosis in chronically activated pathogenic lymphocytes through allosteric modulation of mitochondrial ATP synthase (F1F0-ATPase). This mechanism increases superoxide formation and triggers apoptotic signaling cascades in susceptible cells. Parimifasor demonstrates preferential distribution to the colon with limited systemic exposure and has shown efficacy in preclinical models of colitis. The drug was developed by Lycera and reached Phase 2 clinical trials for ulcerative colitis and plaque psoriasis before development was discontinued[1][3][5][6].

Other names

parimifasor